Regarding “Results of the randomized, placebo-controlled clopidogrel and acetylsalicylic acid in bypass surgery for peripheral arterial disease (CASPAR) trial”  by Conte, Michael S.
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Volume 53, Number 5 Letters to the Editor 1453focused specifically on the association of statin prescription with
AAAs in the title and abstract reported reduced AAA growth in
patients receiving the medication (Table). In contrast, those in
which statin medication was not the primary focus found no
association between statin prescription and AAA growth.3,4
Finally, the only study we are aware of that has reported the
association of statin prescription with the development of AAAs
found no evidence to support a protective effect of this medication.
Forsdahl et al6 performed ultrasound imaging at recruitment and 7
years later in 4000 individuals and reported no reduction in the
incidence of AAA development in individuals prescribed statins. In
fact, statin prescription was positively associated with AAA devel-
opment (odds ratio, 3.77; 95% confidence interval, 1.45-9.81).
The later finding may simply represent a confounding effect of
trying to associate any one factor with an event.
In summary, current evidence does not support the prescrip-
tion of statins to inhibit AAA expansion alone. There is good
evidence for the value of statins in patients with symptomatic
coronary heart and peripheral artery disease, but specific evidence
that statins influence AAA expansion is lacking. Trials designed to
assess the efficacy of a variety of potentially beneficial medications
on AAA expansion are desperately needed, given that early surgical
repair of small AAAs does not reduce mortality.7,8
Craig D. Ferguson, MB, BS (Hons)
Vascular Biology Unit
Department of Surgery
School of Medicine and Dentistry
James Cook University
Townsville, Queensland, Australia
Petra G. Buettner, PhD
School of Public Health
Tropical Medicine and Rehabilitation Sciences
James Cook University
Townsville, Queensland, Australia
Jonathan Golledge, MChir, FRACS
Vascular Biology Unit
Department of Surgery
School of Medicine and Dentistry
James Cook University
Townsville, Queensland, Australia
REFERENCES
1. Takagi H, Matsui M, Umemoto T. A meta-analysis of clinical studies of
statins for prevention of abdominal aortic aneurysm expansion. J Vasc
Surg 2010;52:1675-81.
Table. Association of statin prescription with abdominal a
Follow-up, years
First author Year No. (IQR)
Sweeting3 2010 1701 1.9
Thompson4 2010 1197 3.4 (2.0-6.5)
Ferguson5 2010 652 5 (3-6)
Karlssona 2009 213 NS
Mosorina 2008 121 3.6  2.2
Schlossera 2008 147 3.3
Schoutena 2006 150 3.1 [1.1-13.1]
Sukhijaa 2006 130 2  0.5
IQR, Interquartile range; NS, not stated.
aArticle included in the meta-analysis (refer to Takagi et al1 for citation).2. Heart Protection StudyCollaborativeGroup.Randomized trial of the effects
of cholesterol-lowering with simvastatin on peripheral vascular and other
t
dmajor vascular outcomes in 20,536 people with peripheral arterial disease
and other high-risk conditions. J Vasc Surg 2007;45:645-54.
. Sweeting MJ, Thompson SG, Brown LC, Greenhalgh RM, Powell JT. Use
of angiotensin converting enzyme inhibitors is associated with increased
growth rate of abdominal aortic aneurysms. J Vasc Surg 2010;52:1-4.
. Thompson A, Cooper JA, Fabricius M, Humphries SE, Ashton HA,
Hafez H. An analysis of drug modulation of abdominal aortic aneurysm
growth through 25 years of surveillance. J Vasc Surg 2010;52:55-61:e2.
. Ferguson CD, Clancy P, Bourke B, Walker PJ, Dear A, Buckenham T, et
al. Association of statin prescription with small abdominal aortic aneu-
rysm progression. Am Heart J 2010;159:307-13.
. Forsdahl SH, Singh K, Solberg S, Jacobsen BK. Risk factors for abdom-
inal aortic aneurysms: a 7-year prospective study: the Tromso Study,
1994-2001. Circulation 2009;119:2202-8.
. Ouriel K, Clair DG, Kent KC, Zarins CK. Endovascular repair compared
with surveillance for patients with small abdominal aortic aneurysms. J
Vasc Surg 2010;51:1081-7.
. Lederle FA, Wilson SE, Johnson GR, Reinke DB, Littooy FN, Acher
CW, et al. Immediate repair compared with surveillance of small abdom-
inal aortic aneurysms. N Engl J Med 2002;346:1437-44.
oi:10.1016/j.jvs.2010.08.089
egarding “Results of the randomized, placebo-
ontrolled clopidogrel and acetylsalicylic acid in
ypass surgery for peripheral arterial disease
CASPAR) trial”
The clopidogrel and acetylsalicylic acid in bypass surgery for
eripheral arterial disease (CASPAR) investigators have examined
he question of optimal antithrombotic therapy in lower extremity
ypass (LEB) patients.1 Their data suggest a benefit for the addi-
ion of clopidogrel to standard aspirin therapy in patients under-
oing LEB with prosthetic, although not venous, conduits. Some
dditional information would help to provide context for these
bservations and their implications for everyday practice.
The study design specified that patients were randomized
everal days after completion of the operation. This introduces a
otential selection bias and may limit generalizability of the result.
ere some patients excluded from participation in the trial based
n intraoperative findings or other factors beyond the study exclu-
ion criteria? How representative is the study population of all
atients undergoing LEB operations at these centers?
Prior studies have suggested that the mode of failure for infrain-
uinal prosthetic grafts is notably different than that for venous
rafts.2 Specifically, a higher surgical acuity and rate of clinical deteri-
ration has been noted for prosthetic graft occlusion, related to the
xtension of thrombus into the native vessels. It would be of interest
aneurysm (AAA) growth
Associations with statin
prescriptionusted Analysis
es Linear regression None
es Hierarchical None
es Logistic regression None
o Linear regression Reduced growth
es Linear regression Reduced need for AAA repair
es Linear regression Reduced growth
es Linear regression Reduced growth
o NS Reduced growthortic
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No know if the clinical presentation of graft failure in theCASPAR trial
iffered by treatment group and conduit type.
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May 20111454 Letters to the EditorI take issue with a point made by the authors twice within their
Discussion. Their assertion that clopidogrel reduces the failure rate
of prosthetic grafts to approximate that of venous grafts is un-
founded. This comparison simply cannot be made in their study in
a statistically valid fashion. Patients in the CASPAR trial were not
randomized to conduit; hence, it is highly likely that those patients
who received venous vs prosthetic grafts differed significantly in
key clinical and anatomic variables. The authors did not share the
relevant characteristics of the two conduit subgroups in the report.
Multiple high quality randomized trials have demonstrated the
clear superiority of venous over prosthetic grafts for LEB, even in
the above-knee position.3 The implication that clopidogrel treat-
ment might alter this established paradigm is not substantiated by
their trial, and I think highly speculative.
In comparing the data fromCASPARandbypass versus angioplasty
in severe ischemia of the leg (BASIL)4 to that from North American
studies suchasProjectorEx-VivoveingraftEngineeringviaTransfection
(PREVENT) III,5 I am struck by two persistent observations. Despite
the fact that two-thirdsof thepatients in theCASPARtrialpresentedwith
symptoms of critical ischemia, only 25% of the LEBs performed in this
study were at a tibial or pedal level. In BASIL roughly one-third of the
grafts performed were infrapopliteal, whereas in PREVENT III the
proportion was reversed (two-thirds were tibial/pedal). Therefore, I
question if the results from these trials are relevant to patients requiring
infrapopliteal bypass surgery, which appears more common in current
surgical practice on this side of the Atlantic, particularly in the endovas-
cular era. Finally, all of these trials continue to demonstrate inadequate
medical therapy in LEBpatients, specifically the lowutilization of statins,
whichwere associatedwith abeneficial effect in theCASPARtrial, aswell
as in PREVENTIII.6 Perhaps an intensive-dose statin trialmay still be of
relevance in the LEB population?
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Reply
Thank you for the opportunity to comment on Dr Conte’s
letter, which asks some key questions. Dr Conte comments on the
randomization of patients a few days after the operation. The main
purpose of this study was to examine the benefits of treatment
without increasing the risk of bleeding. Although it could be
i
argued that as thrombus formation can occur intra-operatively
reatment should be started immediately, or indeed pre-surgery,
o one had previously explored the use of two potent antiplatelet
gents in these surgical patients. The decision was therefore taken
o initiate treatment a few days after surgery to ensure hemostasis at
he operation site. Patients were not excluded for reasons other
han protocol exclusion criteria.
Unfortunately, the point about the site of occlusion possibly
eing different between prosthetic and venous grafts cannot be
xplored, as the graft failure endpoint did not require details of the
cclusion site to be documented.
In this study, clopidogrel appeared to reduce prosthetic graft occlu-
ion to a rate found in patients undergoing venous grafting. Dr Conte is
orrect, however, that as randomization toprosthetic or venous graftwas
ot a function of this trial, these two sets of patients are not comparable.
hus, it ismore correct to state that although theocclusion rate appeared
o be reduced to the level seen in this trial’s venous graft group, further
nvestigation is required to confirm this finding.
Regarding the geographic inequality of distal grafts between the
hree trials mentioned in paragraph two, we recruited throughout Eu-
ope from one of the largest surgical trials of clopidogrel, and the distri-
ution was as reported. It may be that in PREVENT III (Project or
x-vivo Vein graft ENgineering via Transfection III) a selection bias for
hemoredistal graft patients probably reflected the fact that venousgrafts
studied in PREVENT III) aremuch preferred for the distal graft site. It
s thus possible that PREVENT III had a selection bias toward themore
istal grafts, rather thanCASPAR(Clopidogrel andAcetylsalicylic acid in
ypass Surgery forPeripheralARterial disease) andBASIL (Bypass versus
ngioplasty in Severe Ischaemia of the Leg) having a selection bias
gainst.
The writer’s observation regarding a statin trial is interesting.
e have tried to garner interest from pharmaceutical companies in
his hypothesis; however, it would necessitate bringing all patients
nto treatment and then providing more aggressive treatment to
he “active group.” The numbers required for such a study appar-
ntly seemed prohibitive to the companies. Interestingly, after our
ecent study of a gene therapy in clopidogrel, similar global statin
reatment rates were observed 5 years on from the CASPAR trial.1
his reflects the fact that peripheral artery disease remains the poor
an of cardiovascular disease: underdiagnosed and undertreated.
ill J. F. Belch, MD, FRCP
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emperature measurements for dose-finding in steam
blation
We very recently demonstrated the safety and efficacy of steam
blation for varicose veins in sheep and humans in a pilot study.1
he effectiveness of endovenous thermal ablative treatments (us-
ng laser, radio frequency of steam) depends primarily on the
mount of energy delivered to the venous wall.2,3 Previously, it was
